PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Specialty Physicians are Poised to Embrace Biosimilars Arriving Imminently to the U.S. Market - The Food & Drug Administration is scheduled to release guidelines for the approval of biosimilars by the end of 2011
Specialty Physicians are Poised to Embrace Biosimilars Arriving Imminently to the U.S. Market

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2011/12/14 - The Food & Drug Administration is scheduled to release guidelines for the approval of biosimilars by the end of 2011.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The U.S. biosimilars market is a fast approaching reality. For example, the Patient Protection and Affordable Care Act of 2010, better known as the healthcare reform introduced by President Barack Obama, includes a provision for the establishment of a Food & Drug Administration (FDA) approval pathway for biosimilars. However, much uncertainty lies ahead, including the market potential as a function of physician adoption of biosimilars, as well as the fact that Amgen’s new Enbrel patent could delay a biosimilar version for 17 years.

New analysis from Frost & Sullivan’s (pharma.frost.com) Specialty Physicians Discuss their Opinions of the United States Biosimilars Market research includes an overview of a panel discussion with specialty physicians who are expected to be among the first users of biosimilars in the U.S. This research previews the thoughts and expectations of practitioners to gain insight into some of the major factors which could influence market uptake.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, title, telephone number, company email address, company Web site, city, state and country.

“Based on this representative sample of physicians, the overall adoption of biosimilars can be expected to experience widespread uptake,” said Frost & Sullivan Industry Manager Jennifer Brice. “This is in light of anticipated access to comparable therapeutic options at a lower cost versus high-cost biologics.”

Main factors with the potential to influence the rate and extent of uptake include cost, safety and efficacy data (including testing in specific patient populations), and reputation of the manufacturer. Biosimilars produced by companies that lack experience in developing and manufacturing biologics may be met with skepticism as opposed to companies with experience and a strong track record in the biologics sector.

“Physicians generally agreed that those companies with a solid reputation and strong track record of producing high-quality products would likely be trusted to bring a quality biosimilar product to market, regardless of geographic location,” said Frost & Sullivan Senior Industry Analyst Debbie Toscano. “Experience with biologics, as opposed to experience with generics, is key. However, many physicians will likely be skeptical of companies based in developing countries such as India or China that lack a strong reputation due to negative past experiences.”

Patients may perceive biologics, as opposed to biosimilars, as superior products simply due to their cost, as many people associate price with quality. A clear explanation of the financial advantages of developing a biosimilar, coupled with strong clinical data to support non-inferiority, may help to improve any negative perceptions of biosimilars. This positive clinical data from well-designed clinical trials may also increase the confidence level of physicians and help alleviate the concern of being forced to prescribe an inferior product. Strong clinical data will be the main driver of initial practitioner acceptance of biosimilars and biobetters.

“Potential skepticism may be overcome with the help of convincing clinical data for products from reputable companies highly experienced with biologics,” said Brice. “As positive real-world experience is gained, uptake is expected to gradually increase.”

Specialty Physicians Discuss their Opinions of the United States Biosimilars Market is part of the Pharmaceuticals & Biotechnology subscription, which also includes research in the following markets: Biosimilars and Follow-On Biologics Americas Conference: The Frost & Sullivan Perspective; Biosimilars–An Emerging Market in Europe; Strategic Analysis of the Indian Biosimilar Market; and Biobetters—Advent of a New Concept. Research included in subscriptions provides detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Specialty Physicians Discuss their Opinions of the United States Biosimilars Market / NA7B-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Specialty Physicians are Poised to Embrace Biosimilars Arriving Imminently to the U.S. Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Britni Myers - Frost.com 
210-477-8481 britni.myers[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)